Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Economic Development, Science and Technology
|
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
|
Policies or Program, Regulation
|
|
Health, Taxation and Finance
|
Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
|
Policies or Program
|
|
Health, Labour
|
Communicating with government officials about federal healthcare plans and benefits.
|
Policies or Program
|
|
Health
|
Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency and modernization, including through the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Health, International Trade, Science and Technology
|
Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
|
Policies or Program
|
|
Health, International Trade
|
Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the life sciences and biopharmaceutical sectors.
|
Policies or Program
|
|
Health
|
Communicating with government officials about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
|
Policies or Program
|
|
Health, Intellectual Property
|
Communicating with government officials about regulations, guidelines, reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
|
Policies or Program
|
|
Health, Intellectual Property
|
Communicating with government officials about regulations related to patented medicines, including the "Patented Medicines (Notice of Compliance) Regulations" (SOR/93-133) under the Patent Act.
|
Regulation
|
|
Health
|
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution
|
|
Science and Technology
|
Communicating with government officials about the Government of Canada's "Biomanufacturing and Life Sciences Strategy" (2021).
|
Policies or Program
|
|
Health, Science and Technology
|
Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023).
|
Policies or Program
|
|
Health, Science and Technology
|
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health, Science and Technology
|
Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.
|
Policies or Program
|
Amgen Canada Canada Inc. serves patients throughout Canada by delivering vital medicines to them. The company also contributes to the development of new therapies (and new uses for existing medicines) in partnership with many of Canada’s leading health care, academic, research, government and patient organizations.
Ugur Gunaydin, General Manager, Canada
Address:
6775 Financial Drive
Mississauga, ON L5N 0A4
Canada
Telephone number:
905-285-3000
Fax number:
905-285-3100
Amgen Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking